Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
- Conditions
- CarcinomaCancer of the SkinBasal Cell CarcinomaSkin CancerCancer of the Skin, Basal Cell
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT05188729
- Locations
- 🇺🇸
ClearlyDerm, Boca Raton, Florida, United States
🇺🇸Life Clinical Trials, Coral Springs, Florida, United States
🇺🇸Affinity Health, Oakbrook Terrace, Illinois, United States
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
- Conditions
- Papillomavirus InfectionsSexually Transmitted Diseases, ViralSkin Diseases, ViralWartsSexually Transmitted DiseasesCondylomata AcuminataSkin Diseases, InfectiousSkin Diseases
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03981822
- Locations
- 🇺🇸
The Indiana Clinical Trials Center,PC, Plainfield, Indiana, United States
🇺🇸DelRicht Research, Tulsa, Oklahoma, United States
🇺🇸Clarkston Skin Research, Clarkston, Michigan, United States
Cantharidin and Occlusion in Verruca Epithelium
- Conditions
- Skin Diseases, InfectiousSkin DiseasesVerrucaCommon WartDNA Virus InfectionsWarts HandVerruca VulgarisPapillomavirus InfectionsSkin Diseases, ViralVirus Diseases
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03487549
- Locations
- 🇺🇸
Cohort 2: Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸Cohort 2: Solutions Through Advanced Research, Jacksonville, Florida, United States
🇺🇸Cohort 2: The Indiana Clinical Trials Center, Plainfield, Indiana, United States
Cantharidin Application in Molluscum Patients
- Conditions
- Molluscum Contagiosum
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 262
- Registration Number
- NCT03377803
- Locations
- 🇺🇸
Bakersfield Dermatology, Bakersfield, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸Redwood Family Dermatology, Santa Rosa, California, United States
Cantharidin Application in Molluscum Patients-1
- Conditions
- Molluscum Contagiosum
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Verrica Pharmaceuticals Inc.
- Target Recruit Count
- 266
- Registration Number
- NCT03377790
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, Birmingham, Alabama, United States
🇺🇸Southeastern Pediatric Associates, Dothan, Alabama, United States
🇺🇸Applied Research Center of Arkansas, Little Rock, Arkansas, United States
- Prev
- 1
- 2
- Next
News
Verrica Pharmaceuticals Launches Global Phase 3 Trial for YCANTH in Common Warts, Targeting 22 Million US Patients
Verrica Pharmaceuticals has initiated a global Phase 3 clinical trial for YCANTH to treat common warts, a condition affecting approximately 22 million patients in the United States with no FDA-approved prescription therapies currently available.
Verrica Pharmaceuticals Reports Record Growth in YCANTH® Dispensed Units for Molluscum Contagiosum Treatment
Verrica Pharmaceuticals achieved a milestone with over 10,000 YCANTH® dispensed applicator units in Q1 2025, representing a 16.7% sequential increase from the previous quarter.
Basal Cell Carcinoma Market Set to Reach $9.7 Billion by 2035, Driven by Early Detection and Novel Therapies
The global basal cell carcinoma market is projected to grow from $5.48 billion in 2024 to $9.7 billion by 2035, exhibiting a CAGR of 5.34% according to IMARC Group research.
Torii Pharmaceutical Submits NDA in Japan for Verrica's Molluscum Contagiosum Treatment, TO-208
Torii Pharmaceutical has submitted a New Drug Application (NDA) in Japan for TO-208, a cantharidin-based treatment for molluscum contagiosum.
Lytix Biopharma's LTX-315 Demonstrates Strong Efficacy in Skin Cancer Trials, Eyes Phase III
Lytix Biopharma's LTX-315 showed an impressive 97% objective response rate in a Phase II study for basal cell carcinoma, potentially as a first-line treatment.
LTX-315 Shows Promise in Phase II Trial for Basal Cell Carcinoma
LTX-315 (VP-315) demonstrated significant anti-cancer effects in a Phase II clinical study for basal cell carcinoma (BCC).
LTX-315 Shows Promise in Basal Cell Carcinoma Treatment
Lytix Biopharma's LTX-315 (VP-315), in partnership with Verrica Pharmaceuticals, demonstrates positive Phase II results for basal cell carcinoma (BCC) treatment.
VP-315 Demonstrates Tumor Reduction in Basal Cell Carcinoma Phase 2 Trial
Preliminary phase 2 data shows VP-315 led to tumor size reduction in 86% of basal cell carcinoma patients, indicating a potential new treatment option.